Form 4: Arbutus Biopharma Director Acquires Stock Options

Richard C. Henriques Jr., a director of Arbutus Biopharma Corp, acquired 67,000 stock options on May 23, 2024, according to a recent SEC filing.

Summary

• On May 23, 2024, Richard C. Henriques Jr., a director of Arbutus Biopharma Corp, was granted 67,000 stock options.
• The exercise price of these options is $3.28 per share.
• The options are fully vested and exercisable as of the grant date.
• The options expire on May 23, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard transaction. The director's acquisition of options could be interpreted as a positive sign of confidence, but it's a routine part of compensation.

Positives

• The director's acquisition of stock options could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This is a standard practice for compensating and incentivizing board members in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biopharmaceutical industry.
• The size of the grant and vesting schedule are typical for director compensation packages.
• Comparable companies like Gilead Sciences or Vertex Pharmaceuticals also utilize stock options as part of their director compensation.

Stakeholder Impact

• The grant of stock options to a director could have a slightly dilutive effect on existing shareholders.

Key Dates